This message was sent to ##Email##
The TOS Fellowship deadline is approaching quickly! Don’t miss your chance to become a Fellow of The Obesity Society — recognizing your significant contributions to the field of obesity research, treatment and prevention.
This is your last opportunity to become a TOS Fellow in 2017.
APPLY BY AUGUST 18
|Closing In Two Weeks — TOS Photo Contest
TOS marketing team is seeking photo submissions of TOS members at work, engaging with patients, working with their staff, instructing a class or conducting research in their lab.
These photos will be used in marketing materials and on our new TOS website.
As if free publicity isn’t enough of a reason to submit your action shots, we’ll also award the top 3 submitters with new TOS merchandise!
Showcase your office. Showcase your talents. Showcase YOU!
SUBMIT BY AUGUST 31 to email@example.com.
FIG Tree Capital Ventures
It has been a pleasure these last few years serving TOS and ASMBS professionals by providing high quality investment opportunities in Energy and Real Estate designed to create Significant Monthly Cash flow and Huge Tax Benefits. If you are interested in learning how we are helping your colleagues put their money to work in some of the most exciting direct investments in the country, stop by Booth # 926.
Washington DC, October 29-November 2
Use promotion code TOSNEW for registration savings!
Veteran Council Liaison/Latin American Affairs Section Presents “Mercedes Carnethon, Obesity and Diabetes: A Public Health Crisis in Hispanic/Latinos”
October 31, 2017
5:15 PM - 6:15 PM
This key lecture explores health disparities in the U.S. Hispanic population. Over 77% of Hispanic/Latino adults are overweight or obese, compared with 67.2% of non-Hispanic whites. It is estimated that 2.5 million, or 10.4% of Hispanic and Latino Americans aged 20 and older have diabetes. Hispanics also are more likely to have undiagnosed diabetes than non-Hispanic whites and non-Hispanic blacks. This symposium will guide the audience through cutting-edge population based research in the US, which is trying to better understand the causes and consequences of these disparities.
Bio-Behavioral Research Section Symposium Presents "The Skinny on GLP-1: CNS Reward Pathways"
November 1, 2017
3:45 PM - 5:15 PM
Glucagon-like peptide-1 (GLP-1) is a gut peptide of high clinical relevance to obesity therapy, exemplified by the FDA approval of GLP-1 analogs for weight loss. Emerging findings are unraveling the brain mechanisms through which GLP-1 analogs reduce food intake, particularly for highly palatable foods. In this session, researchers will present data from both human and animal models revealing the neural mechanisms through which GLP-1 acts in the brain’s cognitive and reward circuitry to reduce food intake and body weight.
GLP-1 and the Mesolimbic Brain Reward System
Matthew R Hayes, PhD
GLP-1, the Lateral Septum and Food Reward
Diana L Williams, PhD
GLP-1 Analog Treatment and the Brain Response to Food Reward
Christos Mantzoros, MD
Are your patients looking for a better iron supplement?
Need patient samples or more information call 800-456-4138 or click here.
|ObesityWeek: WINNER of the 2017 TOPS Research Achievement Award
The Obesity Society is pleased to announce Christos S. Mantzoros, MD, Professor Diabetes and Metabolism at Harvard Medical School & Boston University has been selected by the Awards Committee to receive The Society's highest award for his significant contributions to the field of obesity.
TOPS Research Achievement Award recognizes an individual for singular achievement or contribution to research in the field of obesity.
Rachel Goldman, PhD
Fellowship is one of the highest honors The Obesity Society bestows. This week’s TOS Member Spotlight features a conversation with TOS Fellow Leslie Heinberg.
Q: What is your full name, credentials, and title?
A: Leslie J. Heinberg, PhD, FTOS, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Section Head for Psychology, Department of Psychiatry and Psychology, Cleveland Clinic
Q: What is your primary research question or clinical field?
A: Both my clinical work and research focus on clinically severe obesity, particularly bariatric and metabolic surgery. Although bariatric surgery is the most effective and durable treatment for severe obesity, there is significant variability in outcomes. My goal is to better understand and intervene upon psychological predictors of less optimal outcomes.
Q: How long have you been in your career?
A: I completed my PhD from the University of South Florida in 1993 and my post-doctoral fellowship in Behavioral Medicine from Johns Hopkins University School of Medicine in 1995.
Q: What excites you the most about your work?
A: Patients — it is a real privilege to work with severely obese patients as they embark on a major life change and witness the enormous physical, psychological and quality of life benefits that result from obesity treatment. The primary goal of my clinical work, research and teaching is to help patients achieve their best outcomes in the face of this pernicious, chronic disease.
Q: What advice do you have to offer early career professionals in the field of obesity?
A: Challenge yourself to continuously do things that seem a bit scary and out of your comfort zone: introduce yourself to that “important” person at ObesityWeek, ask a provocative question, share your opinion, submit that paper, join that committee, or apply for that grant. A big part of success is showing up, being tenacious and following through with plans. Read more here.
Environmental influences on Child Health Outcomes (ECHO) is a nationwide NIH-funded research program whose mission is to enhance the health of children for generations to come. The overall scientific goal of the ECHO Cohorts is to investigate associations of a broad array of early environmental influences with child health and development. ECHO prioritizes addressing research questions that have an impact on policies, practices, and programs.
NIH is asking for input on the draft ECHO-wide Cohort data collection protocol through a Request for Information (RFI). The deadline to make comments is August 30 here.
Keeping it Basic: A Review of the Study, "The Cooccurrence of Obesity, Osteoporosis, and Sarcopenia in the Ovariectomized Rat: A Study for Modeling Osteosarcopenic Obesity in Rodents"
Zahra Ezzat Zadeh, PhD, RDN, TOS Early Career Representative
Obesity, osteoporosis and sarcopenia are complex disease conditions that may share underlying pathological and molecular mechanisms, such as energy intake and expenditure, alterations in metabolic and gender related hormones or advancing age. Previous research has found that obesity to sarcopenia is associated, and recent investigations have examined the link between obesity and osteoporosis. This study investigated the cooccurrence of obesity, osteoporosis and sarcopenia within the female body while controlling for energy intake and expenditure and disentangling the effect of chronological aging from estrogen deficiency.
This study received the Recognition Award from the Basic Science Committee at The Obesity Society Annual Meeting in 2015 and was published recently in the June 2017 issue of the Journal of Aging Research by Zahra Ezzat-Zadeh, PhD, RDN and colleagues. The authors investigated the impact of ovarian hormone deficiency, chronological aging, energy intake and energy expenditure on body composition. Two age groups of Sprague-Dawley rats (5 and 10 months old at the beginning of the study) were used to model pre- and post-menopausal women, respectively. The removal of ovaries underlies pathophysiologic obesity followed by osteoporosis that also extends to sarcopenia. Since pair-feeding, the animals ruled out the confounding factor of energy intake; observed excess fat mass suggests a significant decrease in energy expenditure in both age groups. This was partially reflected by decreased 24-hour voluntary wheel running activity that was prevented by estradiol. Administration of estradiol also prevented both an ovariectomy-induced increase in fat mass and a decrease in lean mass including bone mass. Therefore, these alterations in body composition, similar to what manifests as “osteosarcopenic obesity” in post-menopausal women, can be attributed to estradiol, the main ovarian hormone.
In conclusion, this study found that excess adiposity with simultaneous loss of bone and muscle resulted in impaired functionality that accounted for a higher rate of obesity and obesity-related medical complications. Further, it demonstrates how the use of an ovariectomized-rat experimental model allows for an examination of the effect of the loss of ovarian hormones while controlling for energy intake and expenditure in order to conduct obesity and body composition translational research in females without the confounding effect of genetic background.
Notice your jeans getting a little tighter? And having some trouble dragging yourself away from seconds and thirds at the dinner table?
If so, there may be an easy way to shed that excess fat fast — without tweaking your diet or spending your free time at the gym. At least, that’s what makers of the headset Modius claim.
The Huffington Post
Obesity is a multifactorial disease. No surprise there. Environment, advertising, behavior, politics, along with a dozen other factors, play a role. What about your breakfast cereal or wall-to-wall carpeting? In the case of the cereal, unless you’re chowing down on a box or two a day of Frosted Flakes you wouldn’t think so. However, new research is pointing out that chemicals added to breakfast cereals and other everyday products could be contributing to our weight woes.
U.S. Food & Drug Administration
FDA is issuing an update to alert health care providers of five reports of unanticipated deaths that occurred from 2016 to present in patients with liquid-filled intragastric balloon systems used to treat obesity. Four reports involve the Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery, and one report involves the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical Inc.
Artificial sweeteners have been controversial for almost as long as they’ve been around. As early as 1906, President Theodore Roosevelt was compelled to defend the world’s first no-calorie sweetener. “Anybody who says saccharin is injurious to health,” he said, "is an idiot!”
The debate rages on today. Some dietitians and nutritional scientists go to bat for artificial sweeteners like sucralose and stevia as a safe way to enjoy sweet drinks and foods while avoiding the calories.
University of Auckland via Medical Xpress
A new, in-depth study of New Zealand children and teenagers seeking help with weight issues has found their emotional health and well-being is, on average, markedly worse than that of children without weight issues.
Researchers found a concerning level of emotional and behavioral problems, and say these findings highlight how important it is that obesity programs involve psychologists.
| || |
The Obesity Society eNews
Connect with TOS
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Rebecca Truxall, News Editor, The Obesity Society | Contribute News
Robyn Gordon, News Editor, The Obesity Society | Contribute News
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Hope Barton, Content Editor, 469-420-2680 | Contribute news
The Obesity Society
1110 Bonifant Street, Suite 500 | Silver Spring, MD 20910 | 301-563-6526 | Contact Us
Disclaimer: eNews is a digest of the most important news selected for The Obesity Society from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Obesity Society does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of The Obesity Society.
Learn how to add us to your safe sender list so our emails get to your inbox.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063